Skip to Content

Nivolumab plus Ipilimumab – A Potential New Standard-of-Care Treatment Option for Patients with MSI-H/dMMR Advanced Metastatic Colorectal Cancer

Thierry André presents the first results of the CheckMate 8HW study in this MEDtalk from ASCO GI 2024. The study is a randomized phase III study comparing nivolumab + ipilimumab with nivolumab or chemotherapy in patients with MSI-H/dMMR metastatic colorectal cancer, showing promising results for patients with dMMR/MSI-H advanced metastatic colorectal cancer.

Thierry André

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top